The SHWZ stock surged intraday to $0.0009 on March 03, 2026, making Medicine Man Technologies, Inc. (SHWZ) one of the top gainers during market hours. The jump reflects a move from a previous close of $0.0000 to $0.0009, a percentage change of 89900.00% on heavy relative volume. Trading volume climbed to 10,030.00 shares versus an average of 847.00, signaling speculative interest. We examine the drivers, key ratios, and short-term outlook for Medicine Man Technologies on the PNK exchange in the United States. This piece includes Meyka AI market analysis and a model forecast comparison.

SHWZ stock: intraday price and volume action

Medicine Man Technologies, Inc. (SHWZ) traded on PNK in the United States and hit a day high of $0.0009 on March 03, 2026. The stock opened at $0.0001 and the official previous close was $0.0000, producing a dramatic percentage move. Volume reached 10,030.00 shares, a relative volume of 8.30, far above the 50-day average of 847.00 shares. The surge appears driven by low float dynamics and short-term trading interest rather than fundamental releases.

Trading indicators and technicals for SHWZ stock

Short-term indicators show mixed signals: RSI is 48.55, Stochastic %K is 80.29, and ADX is 17.79, indicating low trend strength and choppy action. On balance volume (OBV) is negative at -314,080.00, but money flow (MFI) reads 67.41, reflecting buying pressure during the spike. Momentum metrics underscore extreme volatility with ROC at 89,900.00%, which is a function of tiny base prices rather than sustainable momentum. Traders should expect intraday whipsaw and wide bid-ask spreads on PNK.

Fundamentals and valuation: SHWZ analysis

Medicine Man Technologies operates retail and wholesale cannabis segments with TTM revenue per share of 2.6721 and negative EPS of -0.94, producing a P/E that is not meaningful. Key ratios show a book value per share of 1.8485, current ratio 0.9677, and debt-to-equity 1.6084, indicating leverage stress. Enterprise value to sales is 1.0014, and free cash flow yield is 21.98%, but enterprise value figures reflect legacy liabilities and thin market capitalization ($72,141.00). These metrics suggest structural risk despite pockets of cash generation.

Meyka AI rates SHWZ with a score out of 100 and forecast

Meyka AI rates SHWZ with a score out of 100: 64.05 / 100, Grade B, Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, industry trends, financial growth, key metrics, analyst consensus, and forecast models. Meyka AI’s forecast model projects a monthly level of $0.0100. Compared to the current price of $0.0009, that implies an upside of 1011.11%. Forecasts are model-based projections and not guarantees. Investors should treat the projection as a scenario for high-risk, speculative re-rating rather than a certainty.

Catalysts, risks and near-term outlook for SHWZ stock

Near-term catalysts include the upcoming earnings announcement on 2026-03-26, licensing or retail expansion news, and any sector comparisons published on market platforms. Key risks are low liquidity, high leverage, negative EPS, and regulatory uncertainty in cannabis markets. Analyst consensus data is sparse; third-party comparisons show peer volatility in the specialty cannabis subsector. Given the small market cap and high relative volume, short-term price moves are likely news-driven and not reflective of steady fundamentals.

Where to watch updates and further SHWZ stock coverage

Follow regulatory filings and company updates ahead of the 2026-03-26 earnings date. For peer comparisons and recent tracker data see the Investing.com competitor compare page and a recent press-release feed Investing.com compare. Additional market press context is available via Seeking Alpha press releases. For our live SHWZ tracking visit the Meyka AI stock page at Meyka SHWZ.

Final Thoughts

Key takeaways for SHWZ stock on March 03, 2026: Medicine Man Technologies (SHWZ) posted an intraday top at $0.0009, driven by a volume surge to 10,030.00 shares and a spike in speculative trading. Fundamentals show revenue per share of 2.6721, negative EPS -0.94, a current ratio near 0.97, and debt-to-equity of 1.61, which create downside risk if sentiment fades. Meyka AI rates SHWZ 64.05 / 100 (Grade B, HOLD) and provides a model projection of $0.0100 monthly. That projection implies an upside of 1011.11% versus the current $0.0009 price, but forecasts are model-based projections and not guarantees. For traders, SHWZ may present short-term opportunity tied to news flow and illiquidity. For longer-term investors, the company’s leverage and negative earnings argue for caution until clearer revenue growth and margin improvement appear. Monitor the March 26, 2026 earnings announcement and sector comparisons for confirmatory signals before increasing exposure.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.